RT Journal Article
SR Electronic
T1 Comparing azithromycin to amoxicillin in the management of uncomplicated severe acute malnutrition in Burkina Faso: a pilot randomized trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.15.21258967
DO 10.1101/2021.06.15.21258967
A1 O’Brien, Kieran S.
A1 Sié, Ali
A1 Dah, Clarisse
A1 Ourohire, Millogo
A1 Ouédraogo, Moussa
A1 Boudo, Valentin
A1 Arzika, Ahmed M.
A1 Lebas, Elodie
A1 Nyatigo, Fanice
A1 Godwin, William W.
A1 Kelly, J. Daniel
A1 Arnold, Benjamin F.
A1 Oldenburg, Catherine E.
YR 2021
UL http://medrxiv.org/content/early/2021/06/21/2021.06.15.21258967.abstract
AB Introduction Given the potential for asymptomatic infection in children with uncomplicated severe acute malnutrition (SAM), the World Health Organization recommends a broad-spectrum antibiotic like amoxicillin. Azithromycin is a promising alternative to amoxicillin as it can be administered as a single dose and has efficacy against several pathogens involved in the burden of infectious disease and mortality in this population. In this pilot study, we aimed to establish the feasibility of a larger randomized controlled trial and to provide preliminary evidence comparing the effect of azithromycin to amoxicillin on weight gain in children with uncomplicated SAM.Methods This pilot randomized trial enrolled children 6-59 months old with uncomplicated SAM at 6 healthcare centers in Burkina Faso. Participants were randomized to a single dose of azithromycin or a 7-day course of amoxicillin. All participants received ready-to-use therapeutic food and were followed weekly until nutritional recovery and again at 8 weeks. The primary feasibility outcomes included enrollment potential, refusals, and loss to follow-up. The primary clinical outcome was weight gain (g/kg/day) over the 8-week period. Outcome assessors were masked.Results Between June and October 2020, 312 children were screened, 301 were enrolled with 0 refusals, and 282 (93.6%) completed the 8-week visit. Average weight gain was 2.5 g/kg/day (SD 2.0) in the azithromycin group and 2.6 (SD) 1.7) in the amoxicillin group (Mean Difference - 0.1, 95% CI -0.5 to 0.3, P = 0.63). Fewer adverse events were reported in the azithromycin group (Risk Ratio 0.50, 95% CI 0.31 to 0.82, P = 0.006).Conclusions No differences were found in weight gain between groups. Given the ability to administer a single dose and the potential for fewer adverse events, azithromycin may be an alternative to amoxicillin for uncomplicated SAM. With strong enrollment and follow-up, a larger trial in this setting is feasible.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03568643Clinical Protocols https://pilotfeasibilitystudies.biomedcentral.com/articles/10.1186/s40814-021-00836-w Funding StatementFunding/Support: This work was supported by the National Institute of Child Health and Development at the National Institutes of Health(R21HD100932) and a UCSF REAC award. Role of Funder/Sponsor: The funders reviewed the study design and had no role in the conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Comite dEthique du Burkina Faso and the University of California, San Francisco before study activities began.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified individual participant data (including data dictionaries) will be made available, in addition to study protocols, the statistical analysis plan, and the informed consent form. The data will be made available upon publication to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to catherine.oldenburg{at}ucsf.edu.